Cholera is an infectious disease, caused by intestinal infection with Vibrio cholerae, characterized by massive watery diarrhea and severe dehydration that can lead to shock and death if left untreate...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on cholera is limited due to its extreme rarity, with fewer than 1 in 1,000,000 people affected. This low prevalence restricts the number of systematic clinical studies and comprehensive data collection. Additionally, the lack of identified genetic factors and established inheritance patterns further complicates the understanding of this condition. Despite these challenges, ongoing research aims to better characterize cholera and improve treatment options.
Cholera primarily affects the gastrointestinal system, leading to symptoms such as diarrhea (80-99% of cases), vomiting (30-79%), and severe dehydration (30-79%). Patients may also experience muscle weakness, tachycardia, and hypotension, which are indicative of the body's response to significant fluid loss. The rapid onset of these symptoms can result in serious complications if not promptly addressed.
To navigate cholera effectively, consider consulting an infectious disease specialist who has experience with cholera and its management. While there are currently no specific patient organizations identified, resources such as the Genetic and Rare Diseases Information Center (GARD) can provide valuable information. You may also explore opportunities to participate in clinical trials, which can offer access to new treatments and contribute to the understanding of cholera. For more information about clinical trials, visit ClinicalTrials.gov.
Currently, there is one orphan drug designated for cholera, specifically (+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid, which is still in development. Additionally, there are 13 active clinical trials investigating various aspects of cholera treatment. For more information on these trials, you can visit ClinicalTrials.gov and search for cholera.
Actionable guidance for navigating care for cholera
To navigate cholera effectively, consider consulting an infectious disease specialist who has experience with cholera and its management. While there are currently no specific patient organizations identified, resources such as the Genetic and Rare Diseases Information Center (GARD) can provide valuable information. You may also explore opportunities to participate in clinical trials, which can offer access to new treatments and contribute to the understanding of cholera. For more information about clinical trials, visit ClinicalTrials.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on cholera is limited due to its extreme rarity, with fewer than 1 in 1,000,000 people affected. This low prevalence restricts the number of systematic clinical studies and comprehensive data collection. Additionally, the lack of identified genetic factors and established inheritance patterns further complicates the understanding of this condition. Despite these challenges, ongoing research aims to better characterize cholera and improve treatment options.
Cholera primarily affects the gastrointestinal system, leading to symptoms such as diarrhea (80-99% of cases), vomiting (30-79%), and severe dehydration (30-79%). Patients may also experience muscle weakness, tachycardia, and hypotension, which are indicative of the body's response to significant fluid loss. The rapid onset of these symptoms can result in serious complications if not promptly addressed.
To navigate cholera effectively, consider consulting an infectious disease specialist who has experience with cholera and its management. While there are currently no specific patient organizations identified, resources such as the Genetic and Rare Diseases Information Center (GARD) can provide valuable information. You may also explore opportunities to participate in clinical trials, which can offer access to new treatments and contribute to the understanding of cholera. For more information about clinical trials, visit ClinicalTrials.gov.
Currently, there is one orphan drug designated for cholera, specifically (+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid, which is still in development. Additionally, there are 13 active clinical trials investigating various aspects of cholera treatment. For more information on these trials, you can visit ClinicalTrials.gov and search for cholera.
Actionable guidance for navigating care for cholera
To navigate cholera effectively, consider consulting an infectious disease specialist who has experience with cholera and its management. While there are currently no specific patient organizations identified, resources such as the Genetic and Rare Diseases Information Center (GARD) can provide valuable information. You may also explore opportunities to participate in clinical trials, which can offer access to new treatments and contribute to the understanding of cholera. For more information about clinical trials, visit ClinicalTrials.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on cholera is limited due to its extreme rarity, with fewer than 1 in 1,000,000 people affected. This low prevalence restricts the number of systematic clinical studies and comprehensive data collection. Additionally, the lack of identified genetic factors and established inheritance patterns further complicates the understanding of this condition. Despite these challenges, ongoing research aims to better characterize cholera and improve treatment options.
Cholera primarily affects the gastrointestinal system, leading to symptoms such as diarrhea (80-99% of cases), vomiting (30-79%), and severe dehydration (30-79%). Patients may also experience muscle weakness, tachycardia, and hypotension, which are indicative of the body's response to significant fluid loss. The rapid onset of these symptoms can result in serious complications if not promptly addressed.
To navigate cholera effectively, consider consulting an infectious disease specialist who has experience with cholera and its management. While there are currently no specific patient organizations identified, resources such as the Genetic and Rare Diseases Information Center (GARD) can provide valuable information. You may also explore opportunities to participate in clinical trials, which can offer access to new treatments and contribute to the understanding of cholera. For more information about clinical trials, visit ClinicalTrials.gov.
Currently, there is one orphan drug designated for cholera, specifically (+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid, which is still in development. Additionally, there are 13 active clinical trials investigating various aspects of cholera treatment. For more information on these trials, you can visit ClinicalTrials.gov and search for cholera.
Actionable guidance for navigating care for cholera
To navigate cholera effectively, consider consulting an infectious disease specialist who has experience with cholera and its management. While there are currently no specific patient organizations identified, resources such as the Genetic and Rare Diseases Information Center (GARD) can provide valuable information. You may also explore opportunities to participate in clinical trials, which can offer access to new treatments and contribute to the understanding of cholera. For more information about clinical trials, visit ClinicalTrials.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning cholera
Updated May 11, 2017
The CDC has finalized its recommendation for the cholera vaccine for adults traveling to cholera-affected areas. This decision aims to enhance preventive measures for travelers at risk of exposure.
The CDC advises travelers to Haiti and the Dominican Republic to take precautions against cholera due to its recent spread in these regions. This recommendation comes as cases have been reported since October and November.
The Haitian Ministry of Public Health announced laboratory test results indicating that the cholera strain responsible for the current outbreak is closely related to strains found in South Asia. This information is crucial for understanding the outbreak's origins and guiding public health responses.
The CDC advises Haitian-Americans traveling to Haiti for All Saints' Day and All Souls' Day to take precautions against cholera, which has been spreading since October 21. This guidance aims to protect travelers and mitigate the outbreak's impact.